-
European researchers have shown that targeting the dendritic cell–derived chemokine CCL17 could decrease plaque formation, pointing to a new strategy to treat inflammation associated with cardiovascular and pulmonary …
Published on 6/9/2011
-
Boston University researchers have suggested that using simple sugars as adjuvants could enhance the ability of aminoglycoside antibiotics to treat persistent bacterial infections. The strategy could help improve the …
Published on 6/9/2011
-
Researchers at Roche's Genentech unit have engineered antibodies that slip past the blood brain barrier and hit BACE1. Genentech has moved the antibody into preclinical development for Alzheimer's disease.
Published on 6/2/2011
-
Novartis researchers have used structure-based antigen design to guide the rational optimization of candidate vaccines for RSV and GBS. Although the technique is not new, the work represents proof of concept for its …
Published on 6/2/2011
-
Targets & Mechanisms: Extracting PD Therapy from Coffee Figure 1. Keeping PP2A methylated to treat Parkinson's disease. The coffee-derived compound [a] eicosanoyl-5-hydroxytryptamide (EHT) inhibits demethylation [b] …
Published on 5/26/2011
-
Signum Biosciences and colleagues have shown that a compound found in coffee helps to block the neurotoxic aggregation of alpha-synuclein and thereby improves motor function in mouse models of Parkinson's disease. To …
Published on 5/26/2011
-
A University of Pennsylvania team has found that specific inhibition of HDAC6 increases the immune suppressive functions of T reg cells. The findings point to possible new applications in autoimmune diseases and …
Published on 5/26/2011
-
Targets & Mechanisms: Dendrimer throws a blanket on RA Figure 1. Targeting rheumatoid arthritis on multiple fronts. Rheumatoid arthritis is an autoimmune disease characterized by inflammation, cartilage degradation …
Published on 5/19/2011
-
French researchers have shown that their dendrimer against the receptor for M-CSF blocks inflammation, cartilage degradation and bone erosion in mouse models of rheumatoid arthritis. The team is getting the compound …
Published on 5/19/2011
-
A U.S. team has shown that D-thyroxine, an old hyperlipidemia drug from Abbott, promotes survival in mouse models of sepsis by inhibiting the proinflammatory cytokine MIF. The team is planning a clinical trial of the …
Published on 5/19/2011
-
North American researchers have evidence of a new immune player in type 2 diabetes—B cells that secrete autoreactive antibodies that exacerbate disease. The findings build a case for treating metabolic syndrome and type…
Published on 5/12/2011
-
European researchers have mapped out a pathway that drives early steps in scleroderma and involves serotonin released by activated platelets. The findings could open fibrotic disease as a new therapeutic space for …
Published on 5/12/2011
-
A U.S.-Taiwan team has shown that the proinflammatory cytokine IL-25 exerts potent cytotoxic effects in breast cancer cells and decreases mammary tumor growth in mice. The researchers and an undisclosed company will …
Published on 5/5/2011
-
A Johns Hopkins team has uncovered a role for the MAP kinase pathway in aortic aneurysms caused by the genetic disorder Marfan syndrome. The findings could open a new indication for inhibitors of the pathway already in …
Published on 4/28/2011
-
Targets & Mechanisms: Fighting cancer with inflammation Figure 1. Cancer-fighting inflammation. Findings by Haabeth et al. and Ma et al. support the idea that proinflammatory activity at tumor sites can prevent tumor…
Published on 4/7/2011
-
European researchers have evidence that localized inflammation can help the immune system fight tumors. The findings help build a case for using immunomodulators to stimulate local inflammation as an adjunct to direct …
Published on 4/7/2011
-
U.S. and EU researchers have shown that the generic antimalarial chloroquine could treat pancreatic cancer by inhibiting autophagy. The team already has the drug in Phase II testing.
Published on 4/7/2011
-
Korean researchers have engineered a chimeric, dual-targeting decoy receptor against VEGF-A and TNF-? that showed better efficacy than aflibercept plus Enbrel in mouse models of retinopathy and psoriasis. The group is …
Published on 3/31/2011
-
A Vanderbilt team has found that knocking out the tyrosine kinase Tie1 on vascular endothelial cells in mice decreases the formation of atherosclerotic plaques. The findings could represent a new indication for sanofi-…
Published on 3/31/2011
-
An American team has used a nicotinic acetylcholine receptor agonist to dampen neuroinflammation following ischemia in mice. The finding could open a new indication for compounds from Targacept, EnVivo and Roche.
Published on 3/24/2011
-
Harvard Medical School and Genentech have separately shown that increased MCL1 levels can help tumor cells resist antitubulin agents and BCL2 inhibitors. The findings provide confirmatory evidence to companies already …
Published on 3/17/2011
-
Post-traumatic stress disorder is thought to involve changes in the circuitry of brain regions involved in fear, but the specific molecular players have been elusive. Now, U.S. researchers have evidence that …
Published on 3/17/2011
-
U.K. researchers have shown that the glycoprotein ES-62 prevents and treats septic shock in mice. The group is developing small molecule mimics they believe could help treat septic shock and inflammatory diseases such …
Published on 3/17/2011
-
Targets & Mechanisms: Ohio State's pep(tide) rally Table 1. Ohio State University's peptide-based cancer programs. The Division of Peptide Therapeutics and Cancer Vaccine Research in the Department of Obstetrics and …
Published on 3/10/2011
-
A group at The Ohio State University has advanced its peptide-based cancer vaccines and therapeutics into Phase I trials and late-stage preclinical development with public funding. It is now seeking industry partners to…
Published on 3/10/2011